Busulfan intravenous - SuperGen

Drug Profile

Busulfan intravenous - SuperGen

Alternative Names: Busulfan Partaject

Latest Information Update: 26 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SuperGen
  • Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone marrow transplant rejection
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bone marrow transplant rejection; CNS cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 Dec 2002 Busulfan has received Orphan Drug Status for Bone marrow transplant rejection (Prevention, In paediatric patients)/Myeloablation in USA.
  • 01 Aug 2002 Phase-II clinical trials in CNS cancer in USA (Intravenous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top